The estimated Net Worth of Paul F Truex is at least 2.7 百万$ dollars as of 31 May 2022. Mr. Truex owns over 76,780 units of Cymabay Therapeutics Inc stock worth over 2,493,814$ and over the last 9 years he sold CBAY stock worth over 0$. In addition, he makes 208,493$ as Independent Director at Cymabay Therapeutics Inc.
Paul has made over 3 trades of the Cymabay Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 76,780 units of CBAY stock worth 115,938$ on 31 May 2022.
The largest trade he's ever made was exercising 76,780 units of Cymabay Therapeutics Inc stock on 31 May 2022 worth over 115,938$. On average, Paul trades about 4,339 units every 104 days since 2016. As of 31 May 2022 he still owns at least 76,780 units of Cymabay Therapeutics Inc stock.
You can see the complete history of Mr. Truex stock trades at the bottom of the page.
Paul F. Truex is Independent Director of the Company. Mr. Truex was elected to the Board because of his deep knowledge of, and experience in, the pharmaceutical industry. Mr. Truex is the Executive Chairman of LQT Therapeutics, Inc. and has served in that role since July 2019. Mr. Truex previously served as Executive Chairman of Anthera Pharmaceuticals, Inc., or Anthera, a biopharmaceutical company. Mr. Truex was a founder of Anthera where he served as Director and Chief Executive Officer from September 2004 to December 2016. Prior to founding Anthera, Mr. Truex was a co-founder and served as a Director, President and Chief Executive Officer of Peninsula Pharmaceuticals, Inc., or Peninsula, from the commencement of its operations in October 2001 until December 2005 after which Peninsula was acquired in a series of transactions by Johnson & Johnson and Forest Laboratories. Prior to Peninsula, Mr. Truex was Vice President of Commercial Development for Versicor, Inc. (acquired by Pfizer) from April 2000 to September 2001. From July 1997 to April 2000, Mr. Truex worked at Eli Lilly and Company where he served in various marketing and sales roles. Mr. Truex obtained his M.B.A. in marketing and finance from Indiana University and a B.A. in Economics from the University of Waterloo. Mr. Truex is also a director of Milestone Pharmaceuticals, Inc., where he served as Chairman from 2002 to 2016, Feldan Therapeutics, Inc. and Gladius Pharmaceuticals, Inc. Mr. Truex previously served as a director of Trius Therapeutics, Inc. from June 2008 until September 2013. Because of his more than 25 years of experience in biopharmaceutical and pharmaceutical companies as an executive, as well as his extensive corporate governance and board oversight experience, we believe he is able to make valuable contributions to the Board.
As the Independent Director of Cymabay Therapeutics Inc, the total compensation of Paul Truex at Cymabay Therapeutics Inc is 208,493$. There are 8 executives at Cymabay Therapeutics Inc getting paid more, with Sujal Shah having the highest compensation of 2,556,470$.
Paul Truex is 51, he's been the Independent Director of Cymabay Therapeutics Inc since 2016. There are 11 older and 3 younger executives at Cymabay Therapeutics Inc. The oldest executive at Cymabay Therapeutics Inc is Robert Wills, 66, who is the Independent Chairman of the Board.
Paul's mailing address filed with the SEC is C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL, A8, H4M 2X6.
Over the last 10 years, insiders at Cymabay Therapeutics Inc have traded over 17,635,452$ worth of Cymabay Therapeutics Inc stock and bought 2,170,647 units worth 6,725,086$ . The most active insiders traders include Capital Advisors Llc Aghaza...、Kurt Von Emster、Carl Goldfischer. On average, Cymabay Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of 1,796,241$. The most recent stock trade was executed by Sujal Shah on 13 March 2024, trading 139,119 units of CBAY stock currently worth 656,642$.
cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.
Cymabay Therapeutics Inc executives and other stock owners filed with the SEC include: